Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database
| Autor: | Hyun Jung Kim, Dong Sook Kim, Hyeong Sik Ahn |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty Statin National Health Programs Genital Neoplasms Female medicine.drug_class Population Breast Neoplasms Cohort Studies Breast cancer Internal medicine medicine Humans education Aged Proportional Hazards Models education.field_of_study Cancer prevention Dose-Response Relationship Drug business.industry Incidence Incidence (epidemiology) Hazard ratio Cancer Middle Aged medicine.disease Oncology Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business Cohort study |
| Zdroj: | International Journal of Cancer. 150:1156-1165 |
| ISSN: | 1097-0215 0020-7136 |
| DOI: | 10.1002/ijc.33869 |
| Popis: | Previous studies have reported inconsistent findings concerning the impact of statin use on cancer prevention. This study examined the association between statin use and cancer incidence and mortality related to breast and gynecologic cancers in South Korea. A population-based cohort study was conducted using the National Health Insurance claims database. Women aged 45-70 years old who had taken statins for at least 6 months were compared to statin non-users of the same age from January 2005 to June 2013. The primary outcomes were cancer incidence and mortality related to breast cancer, total gynecologic cancers, cervix uteri cancer, and ovarian cancer. Cox proportional hazards regression was conducted to calculate the adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs). Out of 587 705 women, there were 3591 cases of breast cancer, 2239 cases of gynecologic cancers, and 565 breast and total gynecologic cancer deaths during 7.6 person-years. The aHRs for the association between the risk of each cancer and statin use were 0.88 (95% CI 0.79-0.97) for breast cancer and 0.83 (95% CI 0.67-0.99) for cervix uteri cancer. Statin use was associated with decreased breast cancer mortality (HR = 0.65, 95% CI 0.43-0.99) and total gynecologic cancer mortality (HR = 0.70, 95% CI 0.50-0.98). A dose-response relationship was only found for all-cancer mortality. Statin use for at least 6 months was significantly associated with a lower risk of breast and cervix uteri cancer incidence, and with lower mortality of breast and gynecologic cancers. Further research on these associations will be needed. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text